View Older Stories View More Recent Stories

Jul 20, 2017 07:00AM BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017
Jul 19, 2017 07:00AM Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting
Jul 18, 2017 07:00AM BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City
Jul 13, 2017 07:00AM BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery
Jun 19, 2017 07:00AM Biotime Expands & Advances Ophthalmology Portfolio
Jun 14, 2017 07:02AM BioTime (BTX) Announces Renevia Achieves Primary Endpoint in European Pivotal Trial
Jun 14, 2017 07:00AM BioTime’s Renevia® Achieves Primary Endpoint in European Pivotal Trial
Jun 8, 2017 04:13PM BioTime (BTX) to Announce Top Line Data From Renevia European Pivotal Trial Next Week
Jun 8, 2017 04:10PM BioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial
May 23, 2017 04:30PM BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24
May 23, 2017 07:00AM BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)
May 11, 2017 07:23AM BioTime (BTX) Presents Retinal Restoration Data at ARVO
May 11, 2017 07:00AM BioTime Presents Retinal Restoration Data at ARVO
May 10, 2017 04:01PM BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
May 9, 2017 07:50AM BioTime (BTX) Reports New Data from OpRegen Trial in Dry-AMD at ARVO Meeting
May 9, 2017 07:00AM BioTime Announces New Positive Data from OpRegen® Trial in Dry-AMD
May 8, 2017 07:00AM BioTime Co-CEO Dr. Michael D. West to Present at World Advanced Therapies & Regenerative Medicine Congress on May 17 and 19
Apr 6, 2017 07:00AM BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging
Apr 4, 2017 07:00AM BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6
Mar 28, 2017 07:07AM BioTime (BTX) Announces Key Patents Upheld by European Patent Office
Mar 28, 2017 07:00AM Key BioTime Patents Upheld by European Patent Office
Mar 20, 2017 07:00AM BioTime to Present at Oppenheimer 27th Annual Healthcare Conference
Mar 16, 2017 04:18PM BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments
Feb 21, 2017 06:48AM BioTime (BTX) Reports Deconsolidation of OncoCyte Inc.'s Financial Statements
Feb 21, 2017 06:45AM BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary
Nov 3, 2016 04:01PM BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress
Sep 15, 2016 04:08PM BioTime (BTX) Affirms Announcement of Positive AST-OPC1 SCiSTAR Phase 1/2a Data (AST)
Sep 15, 2016 04:07PM BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial in Patients With Complete Cervical Spinal Cord Injuries
Aug 9, 2016 04:18PM BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments
May 10, 2016 05:01PM BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
Feb 24, 2016 09:03AM BioTime (BTX) Unit Completes End-of-Phase II FDA Meeting for AST-VAC1 in AML
Feb 24, 2016 09:00AM BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy in Acute Myeloid Leukemia
Feb 16, 2016 06:53PM BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents
Feb 1, 2016 01:17PM BioTime, Inc. to Present at Three Investor Conferences in February
Jan 21, 2016 07:03AM Asterias Biotherapeutics (AST) Completes Transer of AST-VAC2 Manufacturing to Cancer Research UK
Jan 21, 2016 07:00AM Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial
Jan 12, 2016 05:27PM Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018
Dec 31, 2015 09:00AM BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common Stock
Dec 11, 2015 07:27PM BioTime Co-Chief Executive Officer Michael D. West, PhD to Deliver Keynote Speech at the 2015 World Stem Cell Summit
Dec 11, 2015 08:50AM BioTime, Inc. Announces Record Date, Distribution Ratio, and Distribution Date for Distribution of Shares of Subsidiary OncoCyte Corporation
Dec 4, 2015 06:00AM BioTime, Inc. to Present at Oppenheimer Annual Healthcare Conference
Nov 18, 2015 08:00AM BioTime, Inc. Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer
Nov 9, 2015 08:00AM BioTime, Inc. Reports Third Quarter 2015 Results and Recent Corporate Accomplishments
Nov 6, 2015 08:00AM BioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to Address the In Vitro Cell Biology Market
Oct 19, 2015 07:00AM Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime, Inc.
Oct 7, 2015 04:15PM BioTime’s Subsidiary OncoCyte Corporation Files Form 10 Registration Statement for Planned Distribution
Oct 1, 2015 03:17PM BioTime Announces the Closing of a $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered
Sep 30, 2015 04:00AM Heraeus Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development and Licensing Agreements
Sep 28, 2015 08:00AM BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
Sep 1, 2015 08:30AM BioTime Chief Executive Officer Dr. Michael D. West to be Keynote Speaker at Stem Cells & Regenerative Medicine Congress 2015
View More Recent Stories View Older Stories